InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.10%
)
US TECH 100
19,959.60
(
0.33%
)
Dow Jones
39,344.79
(
0.00%
)
Brent Oil
85.10
(
-0.37%
)
Bitcoin
57,469.60
(
1.35%
)
Post# of 252526
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 119993
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 97620

Monday, 06/21/2010 5:57:14 PM

Monday, June 21, 2010 5:57:14 PM

Post# of 252526
Oppenheimer MS survey:

73% of neurologists thought use of Copaxone could decrease. On average, Copaxone use could decline by 18.6% if gilenia is approved.

Is the 18.6% figure the average of all of the surveyed neurologists or the average of the 73% who think Gilenia will have an impact?

They estimate Teva's 2011 EPS could drop 6.5% if gilenia is approved.

It will drop much more than that if the FDA approves generic Copaxone :- )


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up